Diffuse Scleroderma clinical trials at University of California Health
11 in progress, 4 open to eligible people
Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
open to eligible people ages 18 years and up
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
at UCLA
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
open to eligible people ages 18 years and up
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
at UCLA
Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-70
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
at UCLA
Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-70
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
at UCLA UCSF
Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
Sorry, currently not accepting new patients, but might later
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).
at UCLA
BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
at UCLA UCSF
CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Sorry, in progress, not accepting new patients
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
at UC Davis
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
at UCLA
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
at UCLA
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Sorry, in progress, not accepting new patients
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
at UCLA UCSD
Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
at UCLA
Our lead scientists for Diffuse Scleroderma research studies include Suzanne Kafaja Augustine Chung Elizabeth Volkmann Emily von Scheven.
Last updated: